Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from MYND Life Sciences ( (TSE:MYND) ).
MYND Life Sciences Inc. announced a management cease trade order (MCTO) due to delays in finalizing their annual financial statements for the year ended October 31, 2024, caused by significant restructuring of the company’s debt and equity. The MCTO restricts trading by the CEO and CFO but does not affect other shareholders. The company expects to complete the filings by April 29, 2025, and is currently on the defaulting issuers list of the British Columbia Securities Commission. MYND Life Sciences is working diligently to meet its filing obligations and will provide further updates as necessary.
More about MYND Life Sciences
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, and diagnostics. The company is engaged in developing new biological and chemical entities with unique molecular concepts for psilocybin applications to overcome diseases, advancing pharmaceutical developments through rigorous science and clinical trials while protecting its intellectual property.
YTD Price Performance: 1.67%
Average Trading Volume: 3,175
Technical Sentiment Signal: Sell
Current Market Cap: $2.67M
For detailed information about MYND stock, go to TipRanks’ Stock Analysis page.